Sage Journals: Discover world-class research

Abstract

Keywords

Hormone replacement therapy premature menopause premature ovarian insufficiency

Get full access to this article

View all access options for this article.

References

Pitkin

Rees

Gray

. Management of premature menopause. Menopause Int 2007; 13: 44–45.

Management of women with premature ovarian insufficiency. Guideline of the European Society of Human Reproduction and Embryology. POI Guideline Development Group, 2015.

Hamoda H, Panay N, Arya R et al. The British Menopause Society & Women’s Health Concern 2016 recommendations on hormone replacement therapy in menopausal women. Post Reproductive Health 2016; 22(4): 165–183.

National Institute for Health and Care Excellence. Menopause: clinical guideline – methods, evidence and recommendations, (NG23), 12 November, Version 1.5, www.nice.org.uk/guidance/ng23/evidence/fullguideline-559549261 (accessed 6 March 2017).

Baber

Panay

. The IMS Writing Group. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric 2016; 19: 109–150.

Manson

Chlebowski

Stefanick

. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA 2013; 310: 1353–1368.

Coulam

Adamson

Annegers

. Incidence of premature ovarian failure. Obstetr Gynecol 1986; 67: 604–606.

Van Kasteren

Hundscheid

RDL

Smits

APT

. Familial idiopathic premature ovarian failure: an overrated and underestimated genetic disease? Hum Reprod 1999; 14: 2455–2459.

Conway

Kaltsas

Patel

. Characterization of idiopathic premature ovarian failure. Fertil Steril 1996; 65: 337–341.

10.

Nelson

. Primary ovarian insufficiency. N Engl J Med 2009; 360: 606–614.

11.

Bachelot

Rouxel

Massin

. Phenotyping and genetic studies of 357 consecutive patients presenting with premature ovarian failure. Eur J Endocrinol 2009; 161: 179–187.

12.

Qin

Jiao

Simpson

. Genetics of primary ovarian insufficiency: new developments and opportunities. Hum Reprod Update 2015; 21: 787–808.

13.

Michala

Goswami

Creighton

. Swyer syndrome: presentation and outcomes. BJOG An Int J Obstet Gynaecol 2008; 115: 737–741.

14.

Wittenberger

Hagerman

Sherman

. The FMR1 premutation and reproduction. Fertil Steril 2007; 87: 456–465.

15.

La Marca

Brozzetti

Sighinolfi

. Primary ovarian insufficiency: autoimmune causes. Curr Opin Obstet Gynecol 2010; 22: 277–282.

16.

Silva

Yamakami

LYS

Aikawa

. Autoimmune primary ovarian insufficiency. Autoimmun Rev 2014; 13: 427–430.

17.

Scottish Intercollegiate Guidelines Network. Long-term follow-up of survivors of childhood cancer. Scottish Intercollegiate Guidelines Network. A national clinical guideline, www.sign.ac.uk/. Edinburgh.

18.

Panay

Fenton

. Iatrogenic menopause following gynecological malignancy: time for action!. Climacteric 2016; 19: 1–2.

19.

Fenton

. Premature ovarian insufficiency: pathogenesis and management. J Midlife Health 2015; 6: 147–153.

20.

Calvet

Grinsztejn

Quintana Mde

. Predictors of early menopause in HIV-infected women: a prospective cohort study. Am J Obstet Gynecol 2015; 212: 765.e1–765.e13.

21.

La Marca

Pati

Orvieto

. Serum anti-mullerian hormone levels in women with secondary amenorrhea. Fertil Steril 2006; 85: 1547–1549.

22.

Gordon

Kannel

Hjortland

. Menopause and coronary heart disease. The Framingham Study. Ann Intern Med 1978; 89: 157–161.

23.

Løkkegaard

Jovanovic

Heitmann

. The association between early menopause and risk of ischaemic heart disease: influence of Hormone Therapy. Maturitas 2006; 53: 226–233.

24.

Rocca

Grossardt

de Andrade

. Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol 2006; 7: 821–828.

25.

Ebong

Watson

Goff

Jr . Age at menopause and incident heart failure: the multi-ethnic study of atherosclerosis. Menopause 2014; 21: 585–591.

26.

Rahman

Akesson

Wolk

. Relationship between age at natural menopause and risk of heart failure. Menopause 2015; 22: 12–16.

27.

Atsma

Bartelink

Grobbee

. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause 2006; 13: 265–279.

28.

Roeters Lennep

Heida

Bots

. Cardiovascular disease risk in women with premature ovarian insufficiency: a systematic review and meta-analysis. Eur J Prev Cardiol 2016; 23: 178–186.

29.

Kalantaridou

Naka

Papanikolaou

. Impaired endothelial function in young women with premature ovarian failure: normalization with hormone therapy. J Clin Endocrinol Metab 2004; 89: 3907–3913.

30.

Langrish

Mills

Bath

. Cardiovascular effects of physiological and standard sex steroid replacement regimens in premature ovarian failure. Hypertension 2009; 53: 805–811.

31.

Collins

Webb

de Villiers

. Cardiovascular risk assessment in women – an update. Climacteric 2016; 19: 329–336.

32.

Kanis

Harvey

Cooper

. Advisory Board of the National Osteoporosis Guideline Group. A systematic review of intervention thresholds based on FRAX: a report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation. Arch Osteoporos 2016; 11: 25–25.

33.

Scientific Advisory Committee on Nutrition: Vitamin D and Health, www.gov.uk/government/groups/scientific-advisory-committee-on-nutrition (2016, accessed 6 March 2017).

34.

Gallagher

. Effect of early menopause on bone mineral density and fractures. Menopause 2007; 14: 567–571.

35.

Kodama

Komura

Kodama

. Estrogen therapy initiated at an early age increases bone mineral density in Turner syndrome patients. Endocr J 2012; 59: 153–159.

36.

Crofton

Evans

Bath

. Physiological versus standard sex steroid replacement in young women with premature ovarian failure: effects on bone mass acquisition and turnover. Clin Endocrinol (Oxf) 2010; 73: 707–714.

37.

Cartwright

Robinson

Seed

. Hormone replacement therapy versus the combined oral contraceptive pill in premature ovarian failure: a randomised controlled trial of the effects on bone mineral density. J Clin Endocrinol Metab 2016; 101: 3497–3505.

38.

Compston J, Cooper A, Cooper C, et al.; The National Osteoporosis Guideline Group (NOGG). Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK. National Osteoporosis Guideline Group (NOGG), 2014.

39.

Khosla

Burr

Caulley

. Bisphosphonate associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007; 22: 1479–1491.

40.

Shane

Burr

Abrahamsen

. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2014; 29: 1–23.

41.

van Kasteren

Schoemaker

. Premature ovarian failure: a systematic review on therapeutic interventions to restore ovarian function and achieve pregnancy. Human Reprod Update 1999; 5: 483–492.

42.

Bidet

Bachelot

Bissauge

. Resumption of ovarian function and pregnancies in 358 patients with premature ovarian failure. J Clin Endocrinol Metab 2011; 96: 3864–3872.

43.

Human Fertilisation and Embryology Authority. Code of Practice: 8th ed. www.hfea.gov.uk/docs/HFEA_Code_of_Practice_8th_Edtion_(Apr_2015).pdf (2015, accessed 6 March 2017).

44.

ESHRE Task Force on Ethics and Law. Ethical considerations for the cryopreservation of gametes and reproductive tissues for self use. Hum Reprod 2004; 19: 460–462.

45.

ESHRE Task Force on Ethics and Law. Oocyte cryopreservation for age-related fertility loss. Hum Reprod 2012; 27: 1231–1237.

46.

Ethics committee of the American Society for Reproductive Medicine. Fertility preservation and reproduction in cancer patients. Fertil Steril 2005; 83: 1622–1628.

47.

Yeh

Steward

Dude

. Pregnancy rates in donor oocyte cycles compared to similar autologous in vitro fertilization cycles: an analysis of 26,457 fresh cycles from the Society for Assisted Reproductive Technology. Fertil Steril 2014; 102: 399–404.

48.

The Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology. Mature oocyte cryopreservation: a guideline. Fertil Steril 2012; 99: 1–7.

49.

Cobo

García-Velasco

Coello

. Oocyte vitrification as an efficient option for elective fertility preservation. Fertil Steril 2016; 105: 755–764e8.

50.

Argyle

Harper

Davies

. Oocyte cryopreservation: where are we now? Hum Reprod Update 2016; 22: 440–449.

51.

Donnez

Dolmans

. Ovarian cortex transplantation: 60 reported live births brings the success and worldwide expansion of the technique towards routine clinical practice. J Assist Reprod Genet 2015; 32: 1167–1170.

52.

Suzuki

Yoshioka

Takae

. Successful fertility preservation following ovarian tissue vitrification in patients with primary ovarian insufficiency. Hum Reprod 2015; 30: 608–615.

53.

Rocca

Bower

Maraganore

. Increased risk of cognitive impairment or dementia in women who under- went oophorectomy before menopause. Neurology 2007; 69: 1074–1083.

54.

Phung

Waltoft

Laursen

. Hysterectomy, oophorectomy and risk of dementia: a nationwide historical cohort study. Dement Geriatr Cogn Disord 2010; 30: 43–50.

55.

Bove

Secor

Chibnik

. Age at surgical menopause influences cognitive decline and Alzheimer pathology in older women. Neurology 2014; 82: 222–229.

56.

Lethaby

Hogervorst

Richards

. Hormone replacement therapy for cognitive function in postmeno- pausal women. Cochrane Database Syst Rev 2008; 1: CD003122–CD003122.

57.

Weber

Maki

McDermott

. Cognition and mood in perimenopause: a systematic review and meta-analysis. J Steroid Biochem Mol Biol 2014; 142: 90–98.

58.

Rocca

Grossardt

Shuster

. Oophorectomy, estrogen, and dementia: a 2014 update. Mol Cell Endocrinol 2014; 389: 7–12.

59.

Faubion

Kuhle

Shuster

. Menopause and considerations for management. Climacteric 2016; 18: 483–491.

60.

Cai

Kallianpur

. Impact of premature ovarian failure on mortality and morbidity among Chinese women. PLoS One 2014; 9: 1–8.

61.

Ewertz

Mellemkjaer

Poulsen

. Hormone use for menopausal symptoms and risk of breast cancer. A Danish cohort study. Br J Cancer 2005; 92: 1293–1297.

62.

Fournier

Berrino

Clavel-Chapelon

. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008; 107: 103–111.

63.

Fournier

Mesrine

Dossus

. Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort. Breast Cancer Res Treat 2014; 145: 535–543.

64.

Canonico

Plu-Bureau

O’Sullivan

. Age at menopause, reproductive history, and venous thromboembolism risk among postmenopausal women: the Women’s Health Initiative Hormone Therapy clinical trials. Menopause 2014; 21: 214–220.

65.

Manzoli

De Vito

Marzuillo

. Oral contraceptives and venous thromboembolism – a systematic review and meta-analysis. Drug Saf 2012; 35: 191–205.

66.

Canonico

Plu-Bureau

Lowe

. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta- analysis. BMJ 2008; 336: 1227–1231.

67.

Canonico

Fournier

Carcaillon

. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler Thromb Vasc Biol 2010; 30: 340–345.

68.

Renoux

Dell’Aniello

Suissa

. Hormone replacement therapy and the risk of venous thromboembolism: a population-based study. J Thromb Haemost 2010; 8: 979–986.

69.

O’Donnell

Warner

Lee

. Physiological sex steroid replacement in premature ovarian failure: randomized crossover trial of effect on uterine volume, endometrial thickness and blood flow, compared with a standard regimen. Hum Reprod 2012; 27: 1130–1138.

70.

The Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1996; 275: 370–375.

71.

Stute P, Neulen J and Wildt L. et al. The impact of micronized progesterone on the endometrium: a systematic review. Climacteric 2016; 7137: 1–13.

72.

Davis

Wahlin-Jacobsen

. Testosterone in women-the clinical significance. Lancet Diabetes Endocrinol 2015; 3: 980–992.

The British Menopause Society and Women’s Health Concern recommendations on the management of women with premature ovarian insufficiency

Abstract

Keywords

Get full access to this article

References